{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:36:11Z","timestamp":1792222571864,"version":"4.4.0"},"reference-count":39,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: B-cells have been suggested to play a role in the pathogenesis of systemic sclerosis (SSc), representing, therefore, a potential therapeutic target. Objectives: We aimed at investigating the 36-month outcomes of 20 SSc patients who underwent an intensified B-depletion therapy (IBCDT) scheme, including both Rituximab (RTX) and cyclophosphamide (CYC). Methods: Data from 20 severe patients (18 females and 2 males, mean age 66.7 \u00b1 11.0 years) with diffuse SSc (anti-topoisomerase I antibody in 95%) patients with multiorgan involvement including interstitial lung disease (ILD) treated with an IBCDT were prospectively collected. IBCDT comprehended: RTX 375 mg\/m2 administered for four weekly doses (on days 1, 8, 15, and 22), followed by two additional doses after 30 and 60 days, in addition to two administrations of 10 mg\/kg of intravenous CYC plus three methylprednisolone pulses (15 mg\/kg) and subsequently followed by oral prednisone rapidly tapered to low minimum dosage of 5 mg daily. In addition, 10 patients with more severe functional respiratory impairment at baseline were also treated with RTX 500 mg every 4 months during the first year and two times a year during the second and the third year. Results: After 36 months of follow-up, we recorded significant amelioration in N-terminal-pro-brain natriuretic peptide (NT-proBNP) levels (mean 385.4 \u00b1 517 pg\/mL at baseline to 279 \u00b1 543 after 36 months). In addition, a significant radiological improvement of ILD in 20% of patients (4\/20) and a radiological stabilization with no sign of progression of interstitial involvement in 13\/20 (65%) were documented. A total of 3 out of 20 (15%) patients experienced a worsening of the ILD. No patient showed further decrease in functional respiratory parameters, including forced vital capacity, forced expiratory volume in one second, and mean values of diffusing capacity for carbon monoxide Moreover, no patient showed any change in the ejection fraction and pulmonary artery pressure when comparing values at baseline and after 24 and 36 months of observation. No severe infection, renal flare, RTX-related side effects were observed. No patient died. Conclusions: Our findings support that the IBCDT was well tolerated and might be a promising therapeutic option for the management of SSc, especially in those subjects with multiorgan involvement that includes ILD.<\/jats:p>","DOI":"10.3390\/jcm10020292","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T11:39:14Z","timestamp":1610624354000},"page":"292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response"],"prefix":"10.3390","volume":"10","author":[{"given":"Daniela","family":"Rossi","sequence":"first","affiliation":[{"name":"Center of Research of Rheumatology, Nephrology and Rare Diseases, Coordinating Center of the Interregional Network of Rare Diseases of Piedmont and Aosta Valley, SCDU CMID-Nephrology and Dialysis G. Bosco Hospital and University of Turin, 10154 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-9441","authenticated-orcid":false,"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[{"name":"Center of Research of Rheumatology, Nephrology and Rare Diseases, Coordinating Center of the Interregional Network of Rare Diseases of Piedmont and Aosta Valley, SCDU CMID-Nephrology and Dialysis G. Bosco Hospital and University of Turin, 10154 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cecchi","sequence":"additional","affiliation":[{"name":"Center of Research of Rheumatology, Nephrology and Rare Diseases, Coordinating Center of the Interregional Network of Rare Diseases of Piedmont and Aosta Valley, SCDU CMID-Nephrology and Dialysis G. Bosco Hospital and University of Turin, 10154 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Saracco","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Mauriziano Umberto I Hospital, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Montabone","sequence":"additional","affiliation":[{"name":"Internal Medicine, San Luigi Gonzaga Hospital Orbassano, 10043 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Modena","sequence":"additional","affiliation":[{"name":"Center of Research of Rheumatology, Nephrology and Rare Diseases, Coordinating Center of the Interregional Network of Rare Diseases of Piedmont and Aosta Valley, SCDU CMID-Nephrology and Dialysis G. Bosco Hospital and University of Turin, 10154 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Pellerito","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Mauriziano Umberto I Hospital, 10128 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Carignola","sequence":"additional","affiliation":[{"name":"Internal Medicine, San Luigi Gonzaga Hospital Orbassano, 10043 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[{"name":"Center of Research of Rheumatology, Nephrology and Rare Diseases, Coordinating Center of the Interregional Network of Rare Diseases of Piedmont and Aosta Valley, SCDU CMID-Nephrology and Dialysis G. Bosco Hospital and University of Turin, 10154 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Allanore Trends in mortality in patients with systemic sclerosis over 40 years: A systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ncprheum0346","article-title":"Mechanisms of Disease: The role of immune cells in the pathogenesis of systemic sclerosis","volume":"2","author":"Sakkas","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort","volume":"69","author":"Hao","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","article-title":"Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease","volume":"45","author":"Liossis","year":"2006","journal-title":"Rheumatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2014A retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ard.2008.095463","article-title":"Rituximab in diffuse cutaneous systemic sclerosis: An open-label clinical and histopathological study","volume":"69","author":"Smith","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3899\/jrheum.120778","article-title":"Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement","volume":"40","author":"Smith","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","article-title":"Emerging targets of disease-modifying therapy for systemic sclerosis","volume":"15","author":"Volkmann","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir","year":"2014","journal-title":"Respirology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: An analysis from the European scleroderma trial and research (EUSTAR) group","volume":"74","author":"Jordan","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.autrev.2017.07.015","article-title":"\u201cHow I treat\u201d autoimmune diseases: State of the art on themanagement of rare rheumatic diseases and ANCA-associated systemic idiopathicvasculitis","volume":"16","author":"Roccatello","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000445841","article-title":"Improved (4 plus 2) Rituximab protocol for severe cases of mixed cryoglobulinemia: A 6-year observational study","volume":"43","author":"Roccatello","year":"2016","journal-title":"Am. J. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.autrev.2016.02.014","article-title":"New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature","volume":"15","author":"Roccatello","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosoppressive maintenance treatment\u2014Clinical response compared to literature and immunological re-assessment","volume":"14","author":"Roccatello","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.advms.2019.03.006","article-title":"Accuracy of Doppler echocardiography in the hemo-dynamic assessment of pulmonary circulation in patients with systemic sclerosis","volume":"64","author":"Bienias","year":"2019","journal-title":"Adv. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"Goldin","year":"2008","journal-title":"Chest"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulo","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9440(10)63328-7","article-title":"B lymphocyte signaling established by the CD19\/CD22 loop regulates autoimmunity in the tight-skin mouse","volume":"165","author":"Asano","year":"2004","journal-title":"Am. J. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","article-title":"Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"R168","DOI":"10.1186\/ar4352","article-title":"Blymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis","volume":"15","author":"Francois","year":"2013","journal-title":"Arthritis. Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"954","DOI":"10.2353\/ajpath.2006.060205","article-title":"B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis","volume":"169","author":"Hasegawa","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"12319","DOI":"10.1073\/pnas.1635114100","article-title":"Systemic and cell type-specific gene expression patterns in scleroderma skin","volume":"100","author":"Whitfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/art.22847","article-title":"B cell infiltration in systemic sclerosis-associated interstitial lung disease","volume":"56","author":"Lafyatis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_29","first-page":"1096","article-title":"SAT0477 Intensified B-cell depletion therapy in progressive systemic sclerosis patients: 24 months follow-up","volume":"77","author":"Rossi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hughes, M., Denton, C.P., and Khanna, D. (2020). Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology, keaa675.","DOI":"10.1093\/rheumatology\/keaa675"},{"key":"ref_31","unstructured":"Goswami, R.P., Ray, A., Chatterjee, M., Mukherjee, A., Sircar, G., and Ghosh, P. (2020). OUP accepted manuscript. Rheumatology, keaa550."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhu, L., Chung, M.P., Gagne, L., Guo, H.H., Guenther, Z., Li, S., Jacobs, S., Morisset, J., Mooney, J.J., and Raj, R. (2020). Rituximab versus mycophenolate in the treatment of recalcitrant connective tissue disease\u2013associated interstitial lung disease. ACR Open Rheumatol.","DOI":"10.1002\/acr2.11210"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.autrev.2018.10.006","article-title":"Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature","volume":"18","author":"Pirola","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-016-1017-y","article-title":"B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: Association with enhanced resolution of skin fibrosis","volume":"18","author":"Daoussis","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00296-010-1697-6","article-title":"Corticosteroids and the risk of scleroderma renal crisis: A systematic review","volume":"32","author":"Trang","year":"2010","journal-title":"Rheumatol. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00296-019-04357-x","article-title":"Targeting very early systemic sclerosis: A case-based review","volume":"39","author":"Melissaropoulos","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.anclin.2015.05.003","article-title":"Physiology considerations in geriatric patients","volume":"33","author":"Alvis","year":"2015","journal-title":"Anesthesiol. Clin."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12931-019-1022-1","article-title":"The natural history of progressive fibrosing interstitial lung diseases","volume":"20","author":"Kolb","year":"2019","journal-title":"Respir. Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/2\/292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:11:14Z","timestamp":1760159474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/2\/292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,14]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["jcm10020292"],"URL":"https:\/\/doi.org\/10.3390\/jcm10020292","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,14]]}}}